-
Nature: Artificial intelligence AI predicts cancer origin and improves the diagnosis of complex metastatic cancer
Time of Update: 2022-11-04
The research team developed an artificial intelligence (AI) system that uses conventional histological sections to accurately find the origin of metastatic tumors and make differential diagnoses of Cancer of Unknown Primary (CUP).
-
ASTRO 2022: Phase 3 clinical results of SBRT combined with sorafenib announced, liver cancer radiotherapy shows better efficacy (NRG/RTOG 1112 study)
Time of Update: 2022-11-04
Stereotactic radiation therapy (SBRT) plus sorafenib (Nexavar) improves overall survival (OS), progression-free survival (PFS), and time to progression (TPP) compared with sorafenib monotherapy in patients with locally advanced hepatocellular carcinoma (HCC).
-
Academician Xu Binghe: Immunotherapy may be a way to break the situation for triple-negative breast cancer
Time of Update: 2022-11-04
The results of translational immunotherapy in advanced triple-negative breast cancer suggest that the spatiotemporal dynamics of tumor invasion immunity in immunocombination therapy:Paclitaxel selectively damages underlying tumor-reactive T cells and DC cells, impairing anti-tumor immunity, thereby affecting the efficacy of atelizumab combination therapy.
-
Tukabrutinib plus trastuzumab has a benefit in HER2+ metastatic colorectal cancer (mCRC).
Time of Update: 2022-11-04
023 Additional analyses based on the Phase 2 MOUNTAINEER trial (NCT04262466) further support the early use of tucatinib (Tukysa) in combination with trastuzumab (Herceptin) as the optimal treatment strategy for previously treated HER2-positive metastatic colorectal cancer (mCRC).
-
AstraZeneca AKT inhibitor for HR-positive breast cancer phase 3 clinical trial reached the primary endpoint!
Time of Update: 2022-11-04
Breast cancer is the most common cancer in the world, of which more than 70% are HR-positive breast cancer, and endocrine therapy is an important treatment for this part of the patient. However, many
-
Predictor of early death from multiple myeloma
Time of Update: 2022-11-04
Poke "Read Original" to see moreThe study included all patients with NDMM ≥aged 18 years aged 18 years enrolled in 36 MRDR facilities from July 2011 to March 2020, and all patients were followed for at least 12 months.
-
European Radiology: Diagnostic evaluation of liver nodules in the 2017 edition of CEUS LI-RADS
Time of Update: 2022-11-04
In 2017, in order to improve the diagnostic accuracy of contrast agent enhanced ultrasound (CEUS) for HCC and promote communication between radiologists, CEUS LI-RADS was introduced clinically as a standardized reporting system for liver nodules in patients at risk of HCC.
-
How did Japan achieve a 5-year survival rate of prostate cancer close to 100%?
Time of Update: 2022-11-04
At present, Japan is recognized worldwide for its ultra-high survival rate in the field of prostate cancer treatment.
According to the statistics of the National Cancer Research Center of Japan, the overall five-year survival rate of prostate cancer in Japan has reached 100% (the five-year survival rate of all prostate cancer patients in China is only 66.
-
ASTRO 2022: Loplatin combination minimizes toxicity of HNSCC
Time of Update: 2022-11-04
For patients with locally advanced head and neck squamous cell carcinoma (HNSCC), docetaxel (Docefrez) gallopplatin (TL) induction chemotherapy plus concurrent roplatin chemoradiotherapy (CRT) versus docetaxel plus cisplatin plus 5-fluorouracil (TPF) induction chemotherapy plus cisplatin CRT based on early findings in a Phase 3 trial (NCT03117257) presented at the 2022 American Society of Radiation Oncology (ASTRO) Annual Meeting.
-
Express Targeted MYC for the treatment of hepatocellular carcinoma! Innovative mRNA therapy completes the first patient dose
Time of Update: 2022-11-04
▲If you have any business needs, please long press to scan the QR code above, or▎WuXi AppTec Content Team Editor Recently, Omega Therapeutics announced the completion of its investigational therapy OTX-2002 in clinical phase 1 trials Dosing of the first patient.
-
Cancer Discovery The next decade of immune checkpoint inhibitors
Time of Update: 2022-11-04
In the past 10 years, immune checkpoint therapy (ICT) led by PD-1/PD-L1 and CTLA-4 inhibitors has made great breakthroughs in clinical practice, and the survival of advanced patients with various cancers, including lung cancer, gastric cancer, colorectal cancer, melanoma, etc.
-
European Radiology: The value of contrast-enhanced mammography for routine breast screening in women
Time of Update: 2022-11-04
The lack of enhanced focus on reconstituted images (Figures B and D) will lead to referral to follow-up This study showed that assessment of rCEM-based women at primary screening was able to reduce biopsy rates by 16.
-
Three-dimensional radiotherapy and intensity-modulated radiotherapy target delineation for rectal cancer
Time of Update: 2022-11-04
Rectal cancer is a common and high-incidence disease in China, which tends to occur in people over the age of 40. Most rectal cancers are sporadic and may also result from certain genetic disorders, b
-
Professor Zhou Caicun: First-line treatment of immune combined chemotherapy brings long-term hope to NSCLC patients
Time of Update: 2022-11-04
Is it necessary to follow KEYNOTE-189 and KEYNOTE-407 with the many PD-(L)1 combination chemotherapy regimens that are currently widely used in clinical practice to demonstrate long-term follow-up OS and PFS data to demonstrate long-term survival benefits?CAN PATIENTS IN THE KEYNOTE-189 AND KEYNOTE-407 STUDIES WHO HAVE NO DISEASE PROGRESSION AT YEAR 5 AFTER TREATMENT WITH DRUG K-THERAPY CONSIDERED CLINICALLY CURED?Recently, this platform invited Professor Zhou Caicun to answer these questions.
-
European Radiology: This MR sign indicates the possibility of IPMN combined with invasive pancreatic cancer
Time of Update: 2022-11-04
In normal pancreatic parenchymal measurements, the pancreas-to-muscle signal-intensity ratio (SIR-I) in the inverting image, the SIR (SIR-T2) in the inverting image, the SIR (SIR-T2) in the T2-weighted image, and the ADC (×10) in the DWI were calculated -3mm2/s) and proton density fat fraction (PDFF [%]) in multi-echo 3D DIXON.
-
Structural Characteristics of Listed Drugs: Analysis of the Development Trend of Small Molecule Drug Properties from "Developability Assessment" (Part I)
Time of Update: 2022-11-04
(3) HBD and HBA numbers are important molecular descriptors that affect drug discovery and CMC development, and are among the oral molecules approved for marketing by the FDA HBA increased over time, but HBD did not change significantly (Figure 1).
-
Professor Ma Jun & Zhu Jun: relma-cel new indications have been approved in China, bringing the dawn of cure for r/r FL patients!
Time of Update: 2022-11-04
RECENTLY, BASED ON THE RESULTS OF RELIANCE, THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA) OF CHINA OFFICIALLY APPROVED THE MARKETING AUTHORIZATION APPLICATION FOR RELMA-CEL FOR THE TREATMENT OF REFRACTORY OR RELAPSED FOLLICULAR LYMPHOMA (R/R FLA) IN ADULTS WHO HAVE UNDERGONE SECOND-LINE OR ABOVE SYSTEMIC THERAPY.
-
Eur Urol Oncol: Prediction of biochemical recurrence after radical prostatectomy based on T stage based on magnetic resonance imaging
Time of Update: 2022-11-04
Recently, researchers from Spain published an article in Eur Urol Oncol comparing various T staging models based on DRE or mpMRI for predicting early biochemical recurrence (BCR) after radical prostatectomy (RP).
-
【CSCO 2022 Preview】Focus on young patients with myeloproliferative tumors
Time of Update: 2022-11-04
com/s/So89sLHqhgN-9HkAQ9n5lA Bone marrow is found in many bones in our body and is the largest hematopoietic organ in the human body, divided into red bone marrow and yellow bone marrow.
-
Do you really understand the molecular structure of LAG-3?
Time of Update: 2022-11-04
preface Over the past decade, the discovery of T cell immune checkpoints (ICPs) and the development of CTLA-4 and PD-1/PD-L1 monoclonal antibody inhibitors have revolutionized the field of immuno-onco
